In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

Afsane Vaezi; Hamed Fakhim; Amir Arastehfar; Tahereh Shokohi; Mohammad T Hedayati; Sadegh Khodavaisy; Ali Rezaei-Matehkolaei; Parisa Badiee; Ferry Hagen; Cornelia Lass-Flörl; Eric Dannaoui; Jacques F Meis; Hamid Badali

doi:10.1111/myc.12716

In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

Afsane Vaezi, Hamed Fakhim, Amir Arastehfar, Tahereh Shokohi, Mohammad T Hedayati, Sadegh Khodavaisy, Ali Rezaei-Matehkolaei, Parisa Badiee, Ferry Hagen, Cornelia Lass-Flörl, Eric Dannaoui, Jacques F Meis, Hamid Badali

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

26 Citations (Scopus)

Abstract

Aspergillus terreus infections are difficult to treat because of the intrinsic resistance to amphotericin B, and higher mortality compared to infections caused by other Aspergillus species. The aim of the present study was to determine the in vitro antifungal activity of amphotericin B and 11 comparators against clinical (n = 36) and environmental (n = 45) A. terreus isolates. In vitro antifungal susceptibility was performed using the CLSI M38-A2 procedure. Amphotericin B exhibited the highest MICs (MIC range, 0.125-4 μg/mL; MIC90 , 2 μg/mL), followed by terbinafine (MIC range, 0.002-1 μg/mL; MIC90 , 1 μg/mL). Only one isolate (1/81) showed amphotericin B MIC above the epidemiologic cut-off value (ECV; 4 μg/mL). None of the isolates had a MIC of ≥ ECV for voriconazole, itraconazole and posaconazole. The reasons for the difference in amphotericin B susceptibility patterns between studies remain unknown. The genetic and species diversity, clinical, environmental and ecological factors in Terrei section on various amphotericin B susceptibility profiles in different countries should be considered more as the main reasons associated with these differences.

Original language	English
Pages (from-to)	134-142
Number of pages	9
Journal	Mycoses
Volume	61
Issue number	2
DOIs	https://doi.org/10.1111/myc.12716
Publication status	Published - Feb 2018

Keywords

Adolescent
Adult
Amphotericin B/pharmacology
Antifungal Agents/pharmacology
Aspergillosis/microbiology
Aspergillus/drug effects
Environmental Microbiology
Female
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Young Adult

Access to Document

10.1111/myc.12716

Cite this

@article{bdaf84fb00324a2c997f8cc5b6d3121a,

title = "In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex",

abstract = "Aspergillus terreus infections are difficult to treat because of the intrinsic resistance to amphotericin B, and higher mortality compared to infections caused by other Aspergillus species. The aim of the present study was to determine the in vitro antifungal activity of amphotericin B and 11 comparators against clinical (n = 36) and environmental (n = 45) A. terreus isolates. In vitro antifungal susceptibility was performed using the CLSI M38-A2 procedure. Amphotericin B exhibited the highest MICs (MIC range, 0.125-4 μg/mL; MIC90 , 2 μg/mL), followed by terbinafine (MIC range, 0.002-1 μg/mL; MIC90 , 1 μg/mL). Only one isolate (1/81) showed amphotericin B MIC above the epidemiologic cut-off value (ECV; 4 μg/mL). None of the isolates had a MIC of ≥ ECV for voriconazole, itraconazole and posaconazole. The reasons for the difference in amphotericin B susceptibility patterns between studies remain unknown. The genetic and species diversity, clinical, environmental and ecological factors in Terrei section on various amphotericin B susceptibility profiles in different countries should be considered more as the main reasons associated with these differences.",

keywords = "Adolescent, Adult, Amphotericin B/pharmacology, Antifungal Agents/pharmacology, Aspergillosis/microbiology, Aspergillus/drug effects, Environmental Microbiology, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Young Adult",

author = "Afsane Vaezi and Hamed Fakhim and Amir Arastehfar and Tahereh Shokohi and Hedayati, {Mohammad T} and Sadegh Khodavaisy and Ali Rezaei-Matehkolaei and Parisa Badiee and Ferry Hagen and Cornelia Lass-Fl{\"o}rl and Eric Dannaoui and Meis, {Jacques F} and Hamid Badali",

note = "{\textcopyright} 2017 Blackwell Verlag GmbH.",

year = "2018",

month = feb,

doi = "10.1111/myc.12716",

language = "English",

volume = "61",

pages = "134--142",

journal = "Mycoses",

issn = "0933-7407",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

AU - Vaezi, Afsane

AU - Fakhim, Hamed

AU - Arastehfar, Amir

AU - Shokohi, Tahereh

AU - Hedayati, Mohammad T

AU - Khodavaisy, Sadegh

AU - Rezaei-Matehkolaei, Ali

AU - Badiee, Parisa

AU - Hagen, Ferry

AU - Lass-Flörl, Cornelia

AU - Dannaoui, Eric

AU - Meis, Jacques F

AU - Badali, Hamid

PY - 2018/2

Y1 - 2018/2

N2 - Aspergillus terreus infections are difficult to treat because of the intrinsic resistance to amphotericin B, and higher mortality compared to infections caused by other Aspergillus species. The aim of the present study was to determine the in vitro antifungal activity of amphotericin B and 11 comparators against clinical (n = 36) and environmental (n = 45) A. terreus isolates. In vitro antifungal susceptibility was performed using the CLSI M38-A2 procedure. Amphotericin B exhibited the highest MICs (MIC range, 0.125-4 μg/mL; MIC90 , 2 μg/mL), followed by terbinafine (MIC range, 0.002-1 μg/mL; MIC90 , 1 μg/mL). Only one isolate (1/81) showed amphotericin B MIC above the epidemiologic cut-off value (ECV; 4 μg/mL). None of the isolates had a MIC of ≥ ECV for voriconazole, itraconazole and posaconazole. The reasons for the difference in amphotericin B susceptibility patterns between studies remain unknown. The genetic and species diversity, clinical, environmental and ecological factors in Terrei section on various amphotericin B susceptibility profiles in different countries should be considered more as the main reasons associated with these differences.

AB - Aspergillus terreus infections are difficult to treat because of the intrinsic resistance to amphotericin B, and higher mortality compared to infections caused by other Aspergillus species. The aim of the present study was to determine the in vitro antifungal activity of amphotericin B and 11 comparators against clinical (n = 36) and environmental (n = 45) A. terreus isolates. In vitro antifungal susceptibility was performed using the CLSI M38-A2 procedure. Amphotericin B exhibited the highest MICs (MIC range, 0.125-4 μg/mL; MIC90 , 2 μg/mL), followed by terbinafine (MIC range, 0.002-1 μg/mL; MIC90 , 1 μg/mL). Only one isolate (1/81) showed amphotericin B MIC above the epidemiologic cut-off value (ECV; 4 μg/mL). None of the isolates had a MIC of ≥ ECV for voriconazole, itraconazole and posaconazole. The reasons for the difference in amphotericin B susceptibility patterns between studies remain unknown. The genetic and species diversity, clinical, environmental and ecological factors in Terrei section on various amphotericin B susceptibility profiles in different countries should be considered more as the main reasons associated with these differences.

KW - Adolescent

KW - Adult

KW - Amphotericin B/pharmacology

KW - Antifungal Agents/pharmacology

KW - Aspergillosis/microbiology

KW - Aspergillus/drug effects

KW - Environmental Microbiology

KW - Female

KW - Humans

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Young Adult

U2 - 10.1111/myc.12716

DO - 10.1111/myc.12716

M3 - Article

C2 - 29064123

SN - 0933-7407

VL - 61

SP - 134

EP - 142

JO - Mycoses

JF - Mycoses

IS - 2

ER -

In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

Abstract

Keywords

Access to Document

Fingerprint

Cite this